Project Grant R43CA298410
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Metastx LLC (EVGVK2KXJNM4)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
The National Cancer Institute (NCI) awarded a $680,433 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Regents of the University of California, San Francisco (UCSF) to conduct a multi-year research project titled "Multimodality Spatial Analysis in Prostate Cancer to Improve Prognostic Estimation and Cast Light into the Black Box of Pathology Artificial Intelligence Algorithms." The goal of this research is to apply cutting-edge spatial proteogenomic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $927,997 to Lagrange Scientific LLC to develop a prognostic assay for metastatic clear cell renal cell carcinoma (cCRCC). The goal is to identify a panel of metabolite biomarkers that can accurately predict early disease progression to metastasis in cCRCC patients, enabling earlier initiation of systemic therapy for aggressive subtypes. The project will utilize...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
This $544,475 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop an in vitro cancer metastasis model system using decellularized organ-specific tissue (biomatrices) to study organ-specific cancer metastasis. The University of Texas Southwestern Medical Center, the awardee, hypothesizes that the biomatrices can recapitulate the organ microenvironment and enable the growth of organ-specific tumor colonies, which can be used to investigate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalized treatment planning of Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy (RPT) for metastatic castration-resistant prostate cancer. The project aims to leverage imaging data from pre-treatment PSMA-PET scans and during-treatment SPECT scans to build predictive models that can estimate...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
The National Cancer Institute (NCI) awarded a $847,322 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Olmeda Biosciences LLC, a small disadvantaged business located in San Diego, CA. The grant, which runs from September 5, 2024 to August 31, 2025, supports the development of a novel, minimally invasive multiplex assay that uses aqueous humor (the clear fluid in the front chamber of the eye) to accurately predict the metastatic risk for patients with uveal melanoma, a...